<?xml version="1.0" encoding="UTF-8"?>
<Label drug="sodium14" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.



 *      Body as a Whole: Weakness. 
 *      Cardiovascular: Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs). 
 *      Digestive: Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia. 
 *      Hematologic: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. 
 *      Hypersensitivity: Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura. 
 *      Metabolic: Electrolyte imbalance (see  PRECAUTIONS  ), hyperglycemia, glycosuria, hyperuricemia. 
 *      Musculoskeletal: Muscle spasm. 
 *      Nervous System/Psychiatric: Vertigo, paresthesias, dizziness, headache, restlessness. 
 *      Skin: Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia. 
 *      Special Senses: Transient blurred vision, xanthopsia. 
 *      Renal: Renal failure, renal dysfunction, interstitial nephritis, (see  WARNINGS  ); hematuria (following intravenous use). 
 *      Urogenital: Impotence. 
    Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.
 

   To report SUSPECTED ADVERSE REACTIONS, contact Oak Pharmaceuticals, Inc. at 1-800-932-5676 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
